Last reviewed · How we verify
PRAZIQUANTEL
At a glance
| Generic name | PRAZIQUANTEL |
|---|---|
| Drug class | Anthelmintic [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium (PHASE3)
- Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention Study
- Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel (PHASE4)
- HIV And Parasitic Infection (HAPI) Study (NA)
- Oxfendazole in Mild Parenchymal Brain Cysticercosis (PHASE2, PHASE3)
- Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis (PHASE4)
- L-PZQ ODT in Schistosoma Infected Children (PHASE3)
- Effectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PRAZIQUANTEL CI brief — competitive landscape report
- PRAZIQUANTEL updates RSS · CI watch RSS